SoylentNews is people
SoylentNews
posted by
janrinok
on Thursday October 15 2015, @01:03PM
from the money-makes-the-world-go-round dept.
from the money-makes-the-world-go-round dept.
U.S. prices for the world's 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters.
The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs in America from industry critics such as Democratic presidential candidate Hillary Clinton.
The 20 medicines, which together accounted for 15 percent of global pharmaceuticals spending in 2014, are a major source of profits for companies including AbbVie (ABBV.N), AstraZeneca (AZN.L), Merck (MRK.N), Pfizer (PFE.N) and Roche (ROG.VX).
This discussion has been archived.
No new comments can be posted.
Transatlantic Divide: How U.S. Pays Three Times More for Drugs
|
Log In/Create an Account
| Top
| 42 comments
| Search Discussion
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
The difference between a Miracle and a Fact is exactly the difference
between a mermaid and a seal.
-- Mark Twain
(Score: 2) by Hyperturtle on Thursday October 15 2015, @10:35PM
This is how a great many things are thus enhanced to improve their value to others, but not necessarily for the original target market.
This is the same as what happened to cable tv, the internet, medical insurance, the political system in the US... None of them are what they used to be, and I think we can probably agree that in my few examples, none of them are what we'd like them to be. Despite everything that has happened to improve them over time, there always has been something to diminish those advances.
I'd rather live today than 100 years ago (if I take off my rose tinted steam punk goggles for a moment) due to the benefits I receive from the advances we've had. And yet it could be so much better if shareholder value and executive board enrichment were less of a concern.